Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283918 · ClinicalTrials.gov registry record
Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 467
- Enrollment target
NCT02283918: Completed study, sponsored by Biogen.
NCT02283918 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 467 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02283918 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 467 participants
- Enrollment target
Study Summary
The primary objective of the study is to develop MS patient-matched healthy population norms for the Multiple Sclerosis Cognition Assessment Battery (MS-COG) that are representative of the United States (US), France, and Italy.
Primary Outcome
The SRT measures verbal learning and memory. A participant is read a list of words and then asked to recall as many of the words as possible. Six learning trials are conducted, followed by a delay trial approximately 20 to 40 minutes later.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-08 |
What the finished NCT02283918 record still lists
NCT02283918 is an observational study that tracks outcomes without assigning an intervention. The registered 467 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02283918 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02283918 about?
NCT02283918 is a clinical study titled "Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery". The primary objective of the study is to develop MS patient-matched healthy population norms for the Multiple Sclerosis Cognition Assessment Battery (MS-COG) that are representative of the United States (US), France, and Italy.
What is the current status of trial NCT02283918?
This trial is currently completed. The enrollment target is 467 participants. The study started on 2014-11. Estimated completion is 2015-08.
Who is sponsoring clinical trial NCT02283918?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06456554 · 467 participants · NA
Acellular Dermal Matrix Investigation in Breast Reconstruction
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia